Acute T-lymphoblastic leukemia relapsed with the character of myeloid/natural killer cell precursor phenotype: a case report.
The leukemic lymphoblasts of a patient expressed CD7, CD13, CD33, CD34, HLA-DR and cytoplasmic CD3varepsilon. He was diagnosed with acute lymphoblastic leukemia (ALL), and successfully treated with a conventional chemotherapy for ALL. The disease relapsed three times, and the character of the cells gradually altered, i.e. CD56 expression increased and CD13, CD7 and cCD3 epsilon decreased. The phenotype of the relapsed ALL was, therefore, compatible with myeloid/natural killer cell precursor acute leukemia (M/NK-AL). Some of M/NK-AL may be closely related with T/myeloid-biphenotypic pro-T blasts, and both types of acute leukemia may develop a tendency to express myeloid antigens, and they may belong to the category of immature T lymphoid precursors.
Hashimoto
Shigeo
S
First Department of Internal Medicine, Niigata University School of Medicine, Asahimachi-dori 1, Niigata City 951-8510, Japan.
Toba
Ken
K
Aoki
Sadao
S
Tsuchiyama
Junjiro
J
Tsukada
Nobuhiro
N
Takahashi
Hidenobu
H
Takahashi
Masuhiro
M
Aizawa
Yoshifusa
Y
D015703:Antigens, CD / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D019070:Cell Lineage; D003131:Combined Modality Therapy; D003630:Daunorubicin / Q000008:administration & dosage; D018450:Disease Progression; D017809:Fatal Outcome; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D005803:Genes, Immunoglobulin; D006021:Glycophorins / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000737:chemistry / Q000473:pathology; D007945:Leukemia, Lymphoid / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D022423:Myeloid Cells / Q000737:chemistry / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D014411:Neoplastic Stem Cells / Q000737:chemistry*; D009195:Peroxidase / Q000032:analysis; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000473:pathology; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D015703:Antigens, CD; D006021:Glycophorins; D006684:HLA-DR Antigens; D009363:Neoplasm Proteins; D014750:Vincristine; D011239:Prednisolone; D009195:Peroxidase; D008727:Methotrexate; D003630:Daunorubicin